Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.

Journal Article (Journal Article)

OBJECT: Gliadel (BCNU) wafer and concomitant temozolomide (TMZ) therapy, when used individually as adjuvant therapies, extend survival from that achieved by resection and radiation therapy (XRT) for glioblastoma multiforme (GBM). It remains unstudied whether combining Gliadel and TMZ therapy is safe or further improves survival in patients with newly diagnosed GBM. The authors reviewed their initial experience utilizing combined Gliadel, TMZ, and radiation therapy for the treatment of GBM. METHODS: All cases involving patients undergoing primary resection of GBM with or without Gliadel wafer (3.85% BCNU) implantation and adjuvant XRT over a 10-year period (1997-2006) were retrospectively reviewed. Beginning in 2004, concomitant TMZ became the standard of care at the authors' institution and all patients with Gliadel implantation also received concomitant TMZ (Stupp protocol). Overall survival and treatment-related morbidity were assessed for all patients treated with Gliadel plus concomitant TMZ (XRT + Gliadel + TMZ). Age-matched (

Full Text

Duke Authors

Cited Authors

  • McGirt, MJ; Than, KD; Weingart, JD; Chaichana, KL; Attenello, FJ; Olivi, A; Laterra, J; Kleinberg, LR; Grossman, SA; Brem, H; Quiñones-Hinojosa, A

Published Date

  • March 2009

Published In

Volume / Issue

  • 110 / 3

Start / End Page

  • 583 - 588

PubMed ID

  • 19046047

Pubmed Central ID

  • PMC4856017

International Standard Serial Number (ISSN)

  • 0022-3085

Digital Object Identifier (DOI)

  • 10.3171/2008.5.17557


  • eng

Conference Location

  • United States